Jacob Rotmensch to Cystadenocarcinoma, Serous
This is a "connection" page, showing publications Jacob Rotmensch has written about Cystadenocarcinoma, Serous.
Connection Strength
0.436
-
A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial. Int J Gynecol Cancer. 2010 Oct; 20(7):1137-41.
Score: 0.347
-
Optimal surgical debulking in uterine papillary serous carcinoma affects survival. Gynecol Oncol. 2011 Jun 01; 121(3):581-5.
Score: 0.090